Moloney Securities Asset Management LLC Reduces Position in IDEXX Laboratories, Inc. $IDXX

Moloney Securities Asset Management LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 931 shares of the company’s stock after selling 214 shares during the quarter. Moloney Securities Asset Management LLC’s holdings in IDEXX Laboratories were worth $499,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IDXX. GAMMA Investing LLC increased its holdings in IDEXX Laboratories by 42.7% in the first quarter. GAMMA Investing LLC now owns 2,187 shares of the company’s stock valued at $918,000 after buying an additional 654 shares during the last quarter. Golden State Wealth Management LLC increased its holdings in IDEXX Laboratories by 3,766.7% in the first quarter. Golden State Wealth Management LLC now owns 116 shares of the company’s stock valued at $49,000 after buying an additional 113 shares during the last quarter. Sequoia Financial Advisors LLC increased its holdings in IDEXX Laboratories by 15.0% in the first quarter. Sequoia Financial Advisors LLC now owns 1,937 shares of the company’s stock valued at $813,000 after buying an additional 252 shares during the last quarter. PDS Planning Inc increased its holdings in IDEXX Laboratories by 3.9% in the first quarter. PDS Planning Inc now owns 641 shares of the company’s stock valued at $269,000 after buying an additional 24 shares during the last quarter. Finally, Diversified Trust Co bought a new stake in IDEXX Laboratories in the first quarter valued at about $633,000. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

IDXX has been the subject of several research analyst reports. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Saturday. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Jefferies Financial Group began coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price for the company. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. Finally, Morgan Stanley upped their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a report on Friday, August 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $656.50.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $640.85 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock has a 50 day simple moving average of $638.40 and a 200-day simple moving average of $559.16. The company has a market cap of $51.27 billion, a PE ratio of 53.36, a P/E/G ratio of 4.15 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP Sharon E. Underberg sold 5,450 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. This represents a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,057 shares of company stock valued at $34,293,468 over the last three months. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.